We advised GH Research on the offering of shares

Davis Polk advised GH Research PLC in connection with its $150 million SEC-registered offering of ordinary shares. The ordinary shares are listed on the Nasdaq Global Market under the ticker symbol “GHRS.”

GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Christian Knoble and Walker Halstad. Partner David R. Bauer and associate Yana Kipnis provided intellectual property advice. Partner Mario J. Verdolini and associate Jeff Metzger  provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post